Substance / Medication

Pembrolizumab

Overview

Active Ingredient
pembrolizumab
RxNorm CUI
1547545
Labeler: Merck Sharp & Dohme LLCUpdated: 2026-02-10T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to berahyaluronidase alfa, hyaluronidase or to any of its excipients.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
A Model-Based Meta-Analysis of Pembrolizumab Effects on Patient-Reported Quality of Life: Advancing Patient-Centered Oncology Drug Development.
Zou Yiqin, Sun Yimeng, Ravva Sudhamshu et al. · CPT Pharmacometrics Syst Pharmacol · 2026
PMID: 41026605Meta-Analysis
Efficacy and safety of pembrolizumab in the treatment of advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Tang Mingyang, Liu Tao, Zhang Yukun et al. · Eur J Clin Pharmacol · 2025
PMID: 40172662Meta-Analysis
Enfortumab Vedotin With or Without Pembrolizumab in Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
Yajima Shugo, Hirose Kohei, Masuda Hitoshi · JAMA Netw Open · 2025
PMID: 40067303Meta-AnalysisFull text (PMC)
Evaluating the clinical benefit of pembrolizumab as a first-line agent in advanced solid tumors: A comprehensive review.
Mohamed Amna, Salman Bushra, Shaikh Asim Jamal · J Oncol Pharm Pract · 2025
PMID: 38710475Meta-Analysis
Clinical Efficacy and Safety of Pembrolizumab Therapy for B-cell Lymphoma: A Systematic Review and Meta-analysis.
Robat-Jazi Behrouz, Habibi Mohammad Amin, Nejati Negar et al. · Anticancer Agents Med Chem · 2025
PMID: 40148307Meta-Analysis
Meta-Analysis of the Efficacy and Safety of Pembrolizumab in the Treatment of Advanced Gastric Cancer and Gastroesophageal Junction Cancer.
Yang Jingyun, Luo Weisheng, Ma Xiaocong et al. · Chemotherapy · 2025
PMID: 38972303Meta-Analysis
Pembrolizumab in gestational trophoblastic neoplasia: Systematic review and meta-analysis with sub-group analysis of potential prognostic factors.
Barcellos Marcio, Braga Antonio, Rech Matheus Machado et al. · Clinics (Sao Paulo) · 2025
PMID: 40031424Meta-AnalysisFull text (PMC)
Efficacy and safety of pembrolizumab in advanced gastric and gastroesophageal junction cancer: a systematic review and meta-analysis.
Ji Xiaoying, Wang Guoping, Pan Dandan et al. · BMC Gastroenterol · 2025
PMID: 40087572Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Pembrolizumab (substance)
SNOMED CT
716125002
UMLS CUI
C3658706
RxNorm CUI
1547545
Labeler
Merck Sharp & Dohme LLC

Clinical Data

This intervention maps to 8 entities in the Ltrl knowledge graph.

8
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.